Trilaciclib for Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.
Are You a Good Fit for This Trial?
This trial is for adults with limited-stage small cell lung cancer who have fully recovered from any previous tumor surgery and whose disease can be measured by scans or tests. Participants must agree to join the study and sign a consent form.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either trilaciclib or placebo to assess myeloprotective effects
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Trilaciclib
Trial Overview
The study compares trilaciclib, a drug given before chemotherapy to protect bone marrow, against a placebo (saline). Participants are randomly assigned to one of the two groups.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Receives trilaciclib
Receives placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pharmacosmos A/S
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.